PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34789301-9 2021 However, under the treatment of ghrelin, cisplatin treatment exhibited a stronger effect on inhibiting P21 expression, upregulating p-CDK1 and cyclin B1 expression, and blocking cell cycle progression. Cisplatin 41-50 cyclin dependent kinase 1 Homo sapiens 134-138 33971703-0 2022 Enrichment of Wee1/CDC2 and NF-kappaB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma. Cisplatin 93-97 cyclin dependent kinase 1 Homo sapiens 19-23 33971703-2 2022 Although the Wee1/CDC2 and NF-kappaB pathways were reported to show abnormal activation in some tumor cells with CDDP resistance, whether there is any concrete connection is currently unclear. Cisplatin 113-117 cyclin dependent kinase 1 Homo sapiens 18-22 33971703-8 2022 In the highly CDDP-tolerant cell lines, Wee1 and RelA were physically crosslinked, which resulted in increased abundance of phosphorylated CDC2 (Y15) and RelA (S536) and consequent modulation of cell cycle progression, survival and proliferation. Cisplatin 14-18 cyclin dependent kinase 1 Homo sapiens 139-143 33971703-11 2022 Conclusion: Simultaneous enrichment of molecules in the Wee1/CDC2 and NF-kappaB pathways and their consequent coactivation is a new molecular mechanism of CDDP resistance in OS cells. Cisplatin 155-159 cyclin dependent kinase 1 Homo sapiens 61-65 34789301-10 2021 Mechanistically, ghrelin promoted S phase cell cycle arrest and upregulated p-CDK1 and cyclin B1 expression induced by cisplatin via inhibition of p38. Cisplatin 119-128 cyclin dependent kinase 1 Homo sapiens 78-82 31059083-11 2019 Compared with cisplatin alone, the combination increased levels of phospho-cyclin-dependent kinase 1 (Y15). Cisplatin 14-23 cyclin dependent kinase 1 Homo sapiens 75-100 35505963-7 2022 Furthermore, we demonstrated that miR-6077 protects LUAD cells from cell death induced by CDDP/PEM via CDKN1A-CDK1-mediated cell-cycle arrest and KEAP1-NRF2-SLC7A11/NQO1-mediated ferroptosis, thus resulting in chemoresistance in multiple LUAD cells both in vitro and in vivo. Cisplatin 90-94 cyclin dependent kinase 1 Homo sapiens 110-114 33336716-0 2020 Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1. Cisplatin 34-43 cyclin dependent kinase 1 Homo sapiens 101-105 32944399-9 2020 DDP, combined with ATF24-PEG-Lipo-beta-E, exerted a synergistic effect on cellular apoptosis and cell arrest at the G2/M phase, and these effects were dependent on the caspase-dependent pathway and Cdc25C/Cdc2/cyclin B1 pathways. Cisplatin 0-3 cyclin dependent kinase 1 Homo sapiens 198-202 25625243-10 2015 In the cisplatin-treated susceptible cells, the levels of phosphorylated Cdc2 and Cdc25C were markedly decreased, leading to a loss of Cdc2 activity and G2/M arrest. Cisplatin 7-16 cyclin dependent kinase 1 Homo sapiens 73-77 29245943-7 2017 Moreover, in the presence of CDDP, Ssd also down-regulates protein phosphatase magnesium-dependent 1 D (PPM1D) and increases the phosphorylation of checkpoint protein kinases (Chk) 1, cell division cycle 25c (Cdc25c) and Cyclin dependent kinase 1 (Cdk1). Cisplatin 29-33 cyclin dependent kinase 1 Homo sapiens 221-246 29245943-7 2017 Moreover, in the presence of CDDP, Ssd also down-regulates protein phosphatase magnesium-dependent 1 D (PPM1D) and increases the phosphorylation of checkpoint protein kinases (Chk) 1, cell division cycle 25c (Cdc25c) and Cyclin dependent kinase 1 (Cdk1). Cisplatin 29-33 cyclin dependent kinase 1 Homo sapiens 248-252 26396928-7 2015 Combination of AITC and cisplatin inhibits the expression of G2/M checkpoint-relevant proteins including CDC2, cyclin B1 and CDC25. Cisplatin 24-33 cyclin dependent kinase 1 Homo sapiens 105-109 31173293-0 2019 Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1. Cisplatin 34-43 cyclin dependent kinase 1 Homo sapiens 101-105 31173293-9 2019 CONCLUSIONS: The present work suggests that OR3A4 participates in regulating cell cycle, cell apoptosis of NSCLC cells and the resistance to cisplatin via upregulating CDK1, indicating that OR3A4 could be identified as a potential therapeutic target for NSCLC patients. Cisplatin 141-150 cyclin dependent kinase 1 Homo sapiens 168-172 25625243-10 2015 In the cisplatin-treated susceptible cells, the levels of phosphorylated Cdc2 and Cdc25C were markedly decreased, leading to a loss of Cdc2 activity and G2/M arrest. Cisplatin 7-16 cyclin dependent kinase 1 Homo sapiens 82-86 25625243-11 2015 In A549/CDDP cells, however, Cdc2 activity was supported by the expression of Cdc2 and Cdc25C after the addition of cisplatin, which resulted in G2/M progression. Cisplatin 116-125 cyclin dependent kinase 1 Homo sapiens 29-33 25625243-11 2015 In A549/CDDP cells, however, Cdc2 activity was supported by the expression of Cdc2 and Cdc25C after the addition of cisplatin, which resulted in G2/M progression. Cisplatin 116-125 cyclin dependent kinase 1 Homo sapiens 78-82 25625243-12 2015 SIGNIFICANCE: The resistance phenotype of G2/M progression has been correlated with dysregulation of Cdc2 in a human lung cancer cell line selected for cisplatin. Cisplatin 152-161 cyclin dependent kinase 1 Homo sapiens 101-105 25376608-9 2015 Loss of the cisplatin-induced checkpoint correlated with decreased Wee1 expression, increased cdc2 activation, and increased mitotic entry (p-histone H3). Cisplatin 12-21 cyclin dependent kinase 1 Homo sapiens 94-98 24756776-5 2014 Forced overexpression of GRP78 protected the cisplatin-sensitive A2780 cells from cisplatin-induced senescence through P53 and CDC2. Cisplatin 45-54 cyclin dependent kinase 1 Homo sapiens 127-131 24756776-5 2014 Forced overexpression of GRP78 protected the cisplatin-sensitive A2780 cells from cisplatin-induced senescence through P53 and CDC2. Cisplatin 82-91 cyclin dependent kinase 1 Homo sapiens 127-131 24756776-6 2014 Knockdown of GRP78 rescued the senescence sensitivity of cisplatin-resistant C13K cells to cisplatin through P21 and CDC2. Cisplatin 57-66 cyclin dependent kinase 1 Homo sapiens 117-121 24756776-6 2014 Knockdown of GRP78 rescued the senescence sensitivity of cisplatin-resistant C13K cells to cisplatin through P21 and CDC2. Cisplatin 91-100 cyclin dependent kinase 1 Homo sapiens 117-121 21570766-4 2011 This synergistic effect was associated with abrogation of CDDP-induced G2/M arrest by down-regulations of phospho-Cdc2 and p21, and inhibitions of phospho-AKT, phospho-ERK and NF-kappaB. Cisplatin 58-62 cyclin dependent kinase 1 Homo sapiens 114-118 24365782-6 2014 As expected, the enhancement in cisplatin toxicity was accompanied by a decrease in the inactive phosphorylated form of cyclin-dependent kinase 1 (CDK1), a key substrate of WEE1, which is indicative of G 2/M checkpoint inactivation. Cisplatin 32-41 cyclin dependent kinase 1 Homo sapiens 120-145 24365782-6 2014 As expected, the enhancement in cisplatin toxicity was accompanied by a decrease in the inactive phosphorylated form of cyclin-dependent kinase 1 (CDK1), a key substrate of WEE1, which is indicative of G 2/M checkpoint inactivation. Cisplatin 32-41 cyclin dependent kinase 1 Homo sapiens 147-151 22355465-10 2012 Selective siRNA depletion of CDK1 increased sensitivity to cisplatin-induced apoptosis (p<0.002). Cisplatin 59-68 cyclin dependent kinase 1 Homo sapiens 29-33 24327015-7 2014 Using small-molecule inhibitors specific for these three proteins also led to growth inhibition of MPM cell lines, and Roscovitine (inhibitor of CDK1) sensitised cells to cisplatin. Cisplatin 171-180 cyclin dependent kinase 1 Homo sapiens 145-149 11093360-1 2000 This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Cisplatin 236-245 cyclin dependent kinase 1 Homo sapiens 119-123 20195699-4 2011 In appropriate conditions, CDDP induced arrest at the G2/M phase accompanied by the enhanced inhibitory phosphorylation of Cdk1 and the elevated protein expression of cyclin B1. Cisplatin 27-31 cyclin dependent kinase 1 Homo sapiens 123-127 20655883-6 2010 Furthermore, cells following knockdown of Plk1, which induced increase of Cyclin B1, p-Cdc2 and p73alpha with a decrease in p-Cdc25C, were more sensitive to CDDP. Cisplatin 157-161 cyclin dependent kinase 1 Homo sapiens 87-91 15868412-7 2005 Finally, the combination of beta-elemene and cisplatin was found to increase the phosphorylation of Cdc2 and Cdc25C, which leads to a reduction in Cdc2-cyclin B1 activity. Cisplatin 45-54 cyclin dependent kinase 1 Homo sapiens 100-104 15868412-7 2005 Finally, the combination of beta-elemene and cisplatin was found to increase the phosphorylation of Cdc2 and Cdc25C, which leads to a reduction in Cdc2-cyclin B1 activity. Cisplatin 45-54 cyclin dependent kinase 1 Homo sapiens 109-113 21592546-5 2011 RESULTS: Cisplatin consistently induced transient S-phase arrest by inhibiting Cdk2/cyclin A complex in S-phase at 12 h and then a durable G2/M-arrest by inhibiting Cdc2/cyclin B complex at 12-18 h. These inhibitions were associated with Chk1 and Chk2 activation and resultant increase in inhibitory tyrosine phosphorylation of Cdk2 and Cdc2. Cisplatin 9-18 cyclin dependent kinase 1 Homo sapiens 165-169 21592546-5 2011 RESULTS: Cisplatin consistently induced transient S-phase arrest by inhibiting Cdk2/cyclin A complex in S-phase at 12 h and then a durable G2/M-arrest by inhibiting Cdc2/cyclin B complex at 12-18 h. These inhibitions were associated with Chk1 and Chk2 activation and resultant increase in inhibitory tyrosine phosphorylation of Cdk2 and Cdc2. Cisplatin 9-18 cyclin dependent kinase 1 Homo sapiens 337-341 15386387-6 2004 In contrast, cells stably expressing H179L-p53 arrested in S-phase following cisplatin treatment, which correlated with a marked decrease in the expression of cdc2, cyclin B1 and cyclin A, and a decrease in CDK2 and cyclin A-associated kinase activity. Cisplatin 77-86 cyclin dependent kinase 1 Homo sapiens 159-163 8406990-10 1993 Our data suggest that the effect of CDDP on cell-cycle phase might be regulated by the dephosphorylation of p34cdc2 protein kinase. Cisplatin 36-40 cyclin dependent kinase 1 Homo sapiens 108-115 9688315-5 1998 At a molecular level, cisplatin enhances cyclin B and p34cdc2 levels and histone H1 kinase activity in non-confluent, but not in confluent, cells. Cisplatin 22-31 cyclin dependent kinase 1 Homo sapiens 54-61 8109984-2 1994 To elucidate how CDDP acts on cell-cycle regulation, we analyzed the effect of CDDP on cell-cycle regulators such as P34cdc2 protein kinase. Cisplatin 17-21 cyclin dependent kinase 1 Homo sapiens 117-124 8109984-2 1994 To elucidate how CDDP acts on cell-cycle regulation, we analyzed the effect of CDDP on cell-cycle regulators such as P34cdc2 protein kinase. Cisplatin 79-83 cyclin dependent kinase 1 Homo sapiens 117-124 8109984-6 1994 The activation of p34cdc2 was inhibited by CDDP. Cisplatin 43-47 cyclin dependent kinase 1 Homo sapiens 18-25 8109984-8 1994 Our data suggested that the effect of CDDP on cell-cycle phase might be regulated by the dephosphorylation of p34cdc2. Cisplatin 38-42 cyclin dependent kinase 1 Homo sapiens 110-117 8109984-9 1994 We hypothesize that inhibition of p34cdc2 dephosphorylation by CDDP is important for its growth-inhibiting properties. Cisplatin 63-67 cyclin dependent kinase 1 Homo sapiens 34-41 9743457-0 1998 Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil. Cisplatin 0-9 cyclin dependent kinase 1 Homo sapiens 32-39 9743457-6 1998 CDDP prevented activation of p34cdc2 by keeping cdc25C inactive and weel active. Cisplatin 0-4 cyclin dependent kinase 1 Homo sapiens 29-36 7574801-3 1995 Our data suggested that arresting cells in the G2-phase of the cell cycle by cisplatin might be regulated by dephosphorylation of cdc2 kinase. Cisplatin 77-86 cyclin dependent kinase 1 Homo sapiens 130-134 8406990-0 1993 Cis-diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung-cancer cells. Cisplatin 0-28 cyclin dependent kinase 1 Homo sapiens 42-49 8406990-2 1993 To elucidate how CDDP acts on cell-cycle regulation, we analyzed the effect of CDDP on cell-cycle regulators such as p34cdc2 protein kinase. Cisplatin 17-21 cyclin dependent kinase 1 Homo sapiens 117-124 8406990-2 1993 To elucidate how CDDP acts on cell-cycle regulation, we analyzed the effect of CDDP on cell-cycle regulators such as p34cdc2 protein kinase. Cisplatin 79-83 cyclin dependent kinase 1 Homo sapiens 117-124 8406990-6 1993 The activation of p34cdc2 protein kinase was inhibited by CDDP. Cisplatin 58-62 cyclin dependent kinase 1 Homo sapiens 18-25 8406990-11 1993 To determine whether the p34cdc2 protein kinase is a primary target for CDDP, we examined the direct effect of CDDP on tyrosine dephosphorylation of p34cdc2 protein kinase in cellular extracts. Cisplatin 111-115 cyclin dependent kinase 1 Homo sapiens 149-156 8406990-14 1993 The dephosphorylation of p34cdc2 protein kinase by okadaic acid was inhibited by CDDP. Cisplatin 81-85 cyclin dependent kinase 1 Homo sapiens 25-32 8406990-15 1993 We hypothesize that inhibition of p34cdc2 dephorphorylation by CDDP is important for its growth-inhibiting properties. Cisplatin 63-67 cyclin dependent kinase 1 Homo sapiens 34-41